The APIs listed below are the main Monoclonal Antibody (mAbs) ingredients that are presently available from LGM Pharma:
- Abciximab
- Adalimumab
- Aflibercept
- Alemtuzumab
- Alirocumab
- Atezolizumab
- Avelumab
- Basiliximab
- Belimumab
- Bevacizumab
- Brentuximab vedotin
- Canakinumab
- Certolizumab pegol
- Cetuximab
- Daclizumab
- Daratumumab
- Denosumab
- Dulaglutide
- Eculizumab
- Efalizumab
- Etanercept
- Evolocumab
- Gemtuzumab
- Golimumab
- Ibritumomab Tiuxetan
- Infliximab
- Ipilimumab
- Ixekizumab
- Matuzumab
- Muromonab-CD3
- Natalizumab
- Nimotuzumab
- Obinutuzumab (Afutuzumab)
- Ofatumumab
- Omalizumab
- Palivizumab
- Panitumumab
- Pembrolizumab
- Pertuzumab
- Ranibizumab
- Rituximab
- Romosozumab
- Secukinumab
- Tocilizumab/ Atlizumab
- Tositumomab
- Trastuzumab
- Ustekinumab
- Vedolizumab
We constantly aim to provide top technical support and full regulatory documentation (TDP / CTD / E-DMF / CEP / US-DMF etc…) even for the most recently approved APIs, originating from EU-GMP certified and US-FDA approved production facilities. Many of the above APIs are manufactured via non-infringing routes of synthesis and would be suitable for Paragraph IV challenges / early launch in regulated markets.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1).
Any patent infringement and resulting liability is solely at buyer risk.
